Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-03-29
2011-03-29
Rawlings, Stephen L (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C530S350000, C530S387100, C530S387300, C530S387700, C530S388100
Reexamination Certificate
active
07915000
ABSTRACT:
Small animal models for assessing immunomodulatory effects of compounds are provided.
REFERENCES:
patent: 3940475 (1976-02-01), Gross
patent: 4289747 (1981-09-01), Chu
patent: 4376110 (1983-03-01), David et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5508717 (1996-04-01), Miller
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5780279 (1998-07-01), Matthews et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5902583 (1999-05-01), Buchsbaum et al.
patent: 5916560 (1999-06-01), Larsen et al.
patent: 6011138 (2000-01-01), Reff et al.
patent: 6040136 (2000-03-01), Garrard et al.
patent: 6338851 (2002-01-01), Gorczynski
patent: 6652858 (2003-11-01), Gorczynski et al.
patent: 6749854 (2004-06-01), Gorczynski et al.
patent: 6955811 (2005-10-01), Gorczynski et al.
patent: 6984625 (2006-01-01), Gorczynski
patent: 7238352 (2007-07-01), Gorczynski et al.
patent: 2002/0031515 (2002-03-01), Caligiura et al.
patent: 2002/0168364 (2002-11-01), Gorczynski et al.
patent: 2002/0192215 (2002-12-01), Hoek et al.
patent: 2003/0017491 (2003-01-01), Shi et al.
patent: 2004/0018972 (2004-01-01), Gorczynski et al.
patent: 2004/0054145 (2004-03-01), Gorczynski
patent: 2004/0175692 (2004-09-01), Bowdish et al.
patent: 2004/0198661 (2004-10-01), Bowdish et al.
patent: 2005/0048069 (2005-03-01), Gorczynski et al.
patent: 2005/0107314 (2005-05-01), Gorczynski et al.
patent: 2005/0129690 (2005-06-01), Bowdish et al.
patent: 2005/0169870 (2005-08-01), Truitt et al.
patent: 2006/0024231 (2006-02-01), Schnitzer et al.
patent: WO-8403508 (1984-09-01), None
patent: WO-8503508 (1985-08-01), None
patent: WO-8806630 (1988-09-01), None
patent: WO-9215679 (1992-09-01), None
patent: WO-9428027 (1994-12-01), None
patent: WO-9518825 (1995-07-01), None
patent: WO-9627011 (1996-09-01), None
patent: WO-9638557 (1996-12-01), None
patent: WO-9708320 (1997-03-01), None
patent: WO-9721450 (1997-06-01), None
patent: WO-9924565 (1999-05-01), None
patent: WO-01/87336 (2001-11-01), None
patent: WO-0211762 (2002-02-01), None
patent: WO-0242332 (2002-05-01), None
patent: WO-02/059280 (2002-08-01), None
patent: WO-02095030 (2002-11-01), None
patent: WO-03025202 (2003-03-01), None
patent: WO 2004/060295 (2004-07-01), None
patent: WO 2004/078938 (2004-09-01), None
patent: WO-2004078937 (2004-09-01), None
patent: WO 2007/084321 (2007-07-01), None
Kneitz et al (Leuk., 13. 98-104, 1999).
Gorczynski,“Evidence for an Immunoregulartory Role of OX2 with its Counter Ligand (OX2L) in the Regulation of Transplant Rejection, Fetal Loss, Autoimmunity and Tumor Growth,” Archibum Immunologiae et Therapiae Experimentalis, 2001, 49, 303-309.
Sahin et al., “New monoclonal antibody specific for a 6.5 kDa glycoprotein which presents mainly on a B cell of chronic lymphocytic leukemia (CLL)” Immunology Letters, 2001, 76, 1-6.
Zou et al. Human Glioma-Induced Immunosuppression Involves Soluble Factor(s) That Alters Monocyte Cytokine Profile and Surface Markers. 1999. vol. 162, pp. 4882-4892.
Brody et al. “Human Cancer Detection and Immunotherapy with Conjugated and Non-Conjugated Monoclonal Antibodies” Anticancer Research 16: 661-674 (1996).
Bauvois et al., Constitutive expression of CD26/dipeptidylpepidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. British Journal of Cancer 1999., vol. 79. p. 1042.
Database Medline, abstract No. NLM16160950, Rioux P. 1999.
Gorczynski, “CD200 and Its Receptors as Targets for Immnoregulation” Current Opinion in Investigational Drugs, Pharmapress, US, vol. 6, No. 5, May 2005, pp. 483-488. XP008051169 ISSN: 1472-4472.
Matutes et al. Morphological and Immuniphenotypic Features of Chronic Lymphocytic Leukemia. Rev. Clin. Exp. Hematol. vol. 4.1, Mar. 2000 p. 22.
Sebestyen et al., Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas. British Journal of Hematology. vol. 104, 1999, p. 412-419.
Alizadeh et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling,” Nature, 403:503-511(2000).
Auchincloss et al. “Strategies to Induce Tolerance,” Transplantation Immunology, Bach and Auchincloss, Eds., Wiley-Liss, New York, Chapter 11, pp. 211-218 (1995).
Bach, “Immunosuppressive therapy of autoimmune diseases,” Immunology Today, 14(6)322-326(1993).
Banerjee, D., et al., “Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats,” Ocular Immunology and Inflammation, 12(2):115-125 (2004).
Barclay and Ward, “Purification and Chemical Characterisation of Membrane Glycoproteins From Rat Thymocytes and Brain, Recognised by Monoclonal Antibody MRC OX2,” European J. Biochemistry, 129:447-458(1982).
Barclay et al.,“CD200 and membrane protein interactions in the control of myeloid cells,” Trends in Immunology, 23(6):2002.
Barclay, A.N., “Different reticular elements in rat lymphoid tissue identified by localization of la, Thy-1 and MRC OX 2 antigens,” Immunology, 44:727-736 (1981).
Barclay, A.N., et al., “Neuronal/Lymphoid Membrane Glycoprotein MRC OX-2 is a Member of the Immunoglobulin Superfamily with a Light-Chain-Like Structure,” Biochem. Soc. Symp., 51:149-157 (1985).
Blazer, B.R., et al., “CD28/B7 Interactions Are Required for Sustaining the Graft-Versus-Leukemia Effect of Delayed Post-Bone Marrow Transplantation Splenocyte Infusion in Murine Recipients of Myeloid or Lymphoid Leukemia Cells,” J. Immunol., 159:3460-3473 (1997).
Bohen, S.P., “Variation in gene expression patterns in follicular lymphoma and the response to rituximab,” PNAS, 100(4):1926-1930(2003).
Boon, Thierry., “Toward a Genetic Analysis of Tumor Rejection Antigens,” Advances in Cancer Res., 58:177-210(1992).
Borriello et al., “MRC OX-2 Defines a Novel T Cell Costimulatory Pathway,” J. Immunol., 158:4549-4554(1997).
Borriello, F., et al., “Characterization and localization of Mox2, the gene encoding the murine homolog of the rat MRC OX-2 membrane glycoprotein,” Mammalian Genome, 9(2):114-118 (1998).
Broderick et al., “Constitutive Retinal CD200 Expression Regulates Resident Microglia and Activin State of Inflammatory Cells During Experimental Autoimmune Uveoretinitis,” Am. J. of Pathology, 161(5):1669-1677(2002).
Bukovsky, A., et al., “Association of lymphoid cell markers with rat ascitic malignant cells,” IRCS Med. Sci., 11:866-867 (1983).
Bukovsky, A., et al., “Association of some cell surface antigens of lymphoid cells and cell surface differentiation antigens with early rat pregnancy,” Immunology, 52:631-640 (1984).
Bukovsky, A., et al., “The localization of Thy-1.1, MRC OX 2 and la antigens in the rat ovary and follopian tube,” Immunology, 48:587-596 (1983).
Bukovsky, A., et al., “The ovarian follicle as a model for the cell-mediated control of tissue growth,” Cell Tissue Res., 236:717-724 (1984).
Caldas et al., “Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen,” Mol. Immunol. 39:941-952 (2003).
Chaouat and Clark, FAS/FAS Ligand Interaction at the Placental Interface is not Required for the Success of Allogeneic Pregnancy in Anti-Paternal MHC Preimmunized Mice, Presented at the 6th Congress of the Adria-Alps Soc. of Immunol. of Reprod., (2000) / Amer. J. of Reprod. Immunol., 45:108-115(2001).
Chen, D., et al., “Discrete Monoclonal Antibodies Define Functionally Important Epitopes in the CD200 Molecule Responsible for Immunosupression Function,” Transplantation, 79:282-288 (2005).
Chen, D., et al., “Synthetic peptides from the N-terminal regionsI of CD200 and CD200R1 modulate immunosu
Bowdish Katherine S.
Kretz-Rommel Anke
Alexion Pharmaceuticals, Inc.
Duffy Brad
Rawlings Stephen L
Ropes & Gray LLP
LandOfFree
Polypeptides and antibodies derived from chronic lymphocytic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides and antibodies derived from chronic lymphocytic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides and antibodies derived from chronic lymphocytic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2680561